Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 7, 2013, Pages 3445-3449

  Chang, Kwok Chiu ^a   Yew, Wing Wai ^b   Cheung, Siu Wai ^c   Leung, Chi Chiu ^a   Tam, Cheuk Ming ^a   Chau, Chi Hung ^d   Wen, Peter Kin Ho ^d   Chan, Raphael Chiu Yeung ^b  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; QUINOLONE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SPUTUM; TUBERCULOSIS;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84879026253     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00388-13     Document Type: Article

References (21)

1. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010globalreportonsurveillanceandresponse. WHO/HTM/TB/2010.3. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/ publications/2010/9789241599191-eng.pdf.
2. Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. 2012. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40:1430-1442.
3. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother. 46:2723-2726. (Pubitemid 34793498)
4. Bressler AM, Zimmer SM, Gilmore JL, Somani J. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4:528-531. (Pubitemid 39077924)
5. Koh W-J, Kwon OJ, Gwak H, Chung JW, Cho S-N, Kim WS, Shim TS. 2009. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 64:388-391.
6. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park S-K, Cho S-N, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518.
7. Bailey EM, Faber MD, Nafziger DA. 2001. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am. J. Kidney Dis. 38:E20.
8. Pfizer. 2008. Zyvox US physician prescribing information. Pfizer, New York, NY.
9. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480. (Pubitemid 34415331)
10. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
11. McKee EE, Ferguson M, Bentley AT, Marks TA. 2006. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob. Agents Chemother. 50:2042-2049. (Pubitemid 43807524)
12. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751.
13. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. 2011. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob. Agents Chemother. 55:567-574.
14. Nuermberger E, Grosset J. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis. 23:243-255. (Pubitemid 38669936)
15. Rodríguez JC, Cebrián L, López M, Ruiz M, Jiménez I, Royo G. 2004. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J. Antimicrob. Chemother. 53:441-444. (Pubitemid 38380240)
16. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. World Health Organization, Geneva, Switzerland.
17. Tobin CM, Sunderland J, White LO, MacGowan AP. 2001. A simple, isocratic high-performance liquid chromatography assay for linezolid in human serum. J. Antimicrob. Chemother. 48:605-608. (Pubitemid 33100305)
18. Lovering AM, Zhang J, Bannister GC, Lankester BJA, Brown JHM, Narendra G, MacGowan AP. 2002. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50:73-77. (Pubitemid 34785257)
19. Tobin CM, Sunderland J, Lovering AM, MacGowan AP. 2003. A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF). J. Antimicrob. Chemother. 51:1041-1042. (Pubitemid 36503445)
20. Koh W-J, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. 2012. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 67:1503-1507.
21. Saralaya D, Peckham DG, Hulme B, Tobin CM, Denton M, Conway S, Etherington C. 2004. Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. J. Antimicrob. Chemother. 53:325-328. (Pubitemid 38239969)